Befotertinib restored chemosensitivity to multidrug-resistant cancer cells by inhibiting the drug efflux activity of ABCB1
These results identify befotertinib as a functional inhibitor of ABCB1 with the capacity to reverse MDR. The findings support its potential as a repurposed agent for combination therapy in tumors with high ABCB1 expression, offering a practical strategy to enhance chemotherapy efficacy.
Authors
- Tai‐Ho Hung (ORCID: https://orcid.org/0000-0003-2354-7060)
- Megumi Murakami (ORCID: https://orcid.org/0000-0002-3920-2166)
- Chung-Pu Wu
- Yen-Ching Li
- Yu-Shan Wu
- Suresh V Ambudkar
- Yang-Hui Huang
Institutions
- Memorial Hospital of South Bend (US)
- Tunghai University (TW)
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Keelung Chang Gung Memorial Hospital (TW)
- National Cancer Institute (US)
Publication Details
- Journal
- Journal of Pharmacy and Pharmacology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1093/jpp/rgag020
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00